BLINCYTO^® (blinatumomab) For Injection, for Intravenous (IV) Use for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

Please see Important Safety Information, including Boxed WARNINGS, on pages 11 and 12. Please see accompanying full prescribing information for BLINCYTO^®.AdvertorialPharmaceutical ReviewWARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES See full prescribing information for complete boxed warning. Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO^®. Interrupt or discontinue BLINCYTO^® as recommended.